A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

被引：8

作者：

Assouline, Sarit ^{[1
]}

Michaelis, Laura C. ^{[2
]}

Othus, Megan ^{[3
]}

Hay, Annette E. ^{[4
]}

Walter, Roland B. ^{[5
]}

Jacoby, Meagan A. ^{[6
]}

Schroeder, Mark A. ^{[6
]}

Uy, Geoffrey L. ^{[6
]}

Law, Lisa Y. ^{[7
]}

Cheema, Faisal ^{[8
]}

Sweet, Kendra L. ^{[9
]}

Asch, Adam S. ^{[10
]}

Liu, Jijun ^{[11
]}

Moseley, Anna B. ^{[2
]}

Maher, Tracy ^{[12
]}

Kingsbury, Laura L. ^{[12
]}

Fang, Min ^{[5
]}

Radich, Jerald ^{[5
]}

Little, Richard F. ^{[13
]}

Erba, Harry P. ^{[14
]}

机构：

[1] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

[2] Med Coll Wisconsin, Milwaukee, WI USA

[3] SWOG Stat & Data Management Ctr, Seattle, WA USA

[4] Queens Univ, Kingston, ON, Canada

[5] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Washington Univ, Sch Med, St Louis, MO USA

[7] Kaiser Permanente NCAL, Roseville, CA USA

[8] Kaiser Permanente, Santa Clara, CA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Oklahoma HSC, Oklahoma City, OK USA

[11] Illinois Canc Care Heartland NCORP, Peoria, IL USA

[12] SWOG Data Operat Ctr, Canc Res & Biostat, Seattle, WA USA

[13] Natl Canc Inst, Canc Therapy & Evaluat Program CTEP, Bethesda, MD USA

[14] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 02期

基金：

美国国家卫生研究院;

关键词：

CONVENTIONAL-CARE-REGIMENS; THERAPY;

D O I：

10.1080/10428194.2022.2148212

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：473 / 477

页数：5

共 18 条

[11] The structural basis for autoinhibition of FLT3 by the juxtamembrane domain [J].

Griffith, J ;

Black, J ;

Faerman, C ;

Swenson, L ;

Wynn, M ;

Lu, F ;

Lippke, J ;

Saxena, K .

MOLECULAR CELL, 2004, 13 (02) :169-178

[12] TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype [J].

Sallman, David A. ;

McLemore, Amy F. ;

Aldrich, Amy L. ;

Komrokji, Rami S. ;

McGraw, Kathy L. ;

Dhawan, Abhishek ;

Geyer, Susan ;

Hou, Hsin-An ;

Eksioglu, Erika Adriana ;

Sullivan, Amy ;

Warren, Sarah ;

MacBeth, Kyle J. ;

Meggendorfer, Manja ;

Haferlach, Torsten ;

Boettcher, Steffen ;

Ebert, Benjamin L. ;

Al-Ali, Najla ;

Lancet, Jeffrey E. ;

Cleveland, John L. ;

Padron, Eric ;

List, Alan F. .

BLOOD, 2020, 136 (24) :2812-2823

[13]

Serroukh, 2022, BLOOD REV

[14] Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia [J].

Vadakekolathu, Jayakumar ;

Minden, Mark D. ;

Hood, Tressa ;

Church, Sarah E. ;

Reeder, Stephen ;

Altmann, Heidi ;

Sullivan, Amy H. ;

Viboch, Elena J. ;

Patel, Tasleema ;

Ibrahimova, Narmin ;

Warren, Sarah E. ;

Arruda, Andrea ;

Liang, Yan ;

Smith, Thomas H. ;

Foulds, Gemma A. ;

Bailey, Michael D. ;

Gowen-MacDonald, James ;

Muth, John ;

Schmitz, Marc ;

Cesano, Alessandra ;

Pockley, A. Graham ;

Valk, Peter J. M. ;

Lowenberg, Bob ;

Bornhaeuser, Martin ;

Tasian, Sarah K. ;

Rettig, Michael P. ;

Davidson-Moncada, Jan K. ;

DiPersio, John F. ;

Rutella, Sergio .

SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (546)

[15] Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia [J].

Walter, Roland B. ;

Michaelis, Laura C. ;

Othus, Megan ;

Uy, Geoffrey L. ;

Radich, Jerald P. ;

Little, Richard F. ;

Hita, Sandi ;

Saini, Lalit ;

Foran, James M. ;

Gerds, Aaron T. ;

Klepin, Heidi D. ;

Hay, Annette E. ;

Assouline, Sarit ;

Lancet, Jeffrey E. ;

Couban, Stephen ;

Litzow, Mark R. ;

Stone, Richard M. ;

Erba, Harry P. .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) :E49-E52

[16] The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia [J].

Williams, Patrick ;

Basu, Sreyashi ;

Garcia-Manero, Guillermo ;

Hourigan, Christopher S. ;

Oetjen, Karolyn A. ;

Cortes, Jorge E. ;

Ravandi, Farhad ;

Jabbour, Elias J. ;

Al-Hamal, Zainab ;

Konopleva, Marina ;

Ning, Jing ;

Xiao, Lianchun ;

Lopez, Juliana Hidalgo ;

Kornblau, Steve M. ;

Andreeff, Michael ;

Flores, Wilmer ;

Bueso-Ramos, Carlos ;

Blando, Jorge ;

Galera, Pallavi ;

Calvo, Katherine R. ;

Al-Atrash, Gheath ;

Allison, James P. ;

Kantarjian, Hagop M. ;

Sharma, Padmanee ;

Daver, Naval G. .

CANCER, 2019, 125 (09) :1470-1481

[17] Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents [J].

Yang, H. ;

Bueso-Ramos, C. ;

DiNardo, C. ;

Estecio, M. R. ;

Davanlou, M. ;

Geng, Q-R ;

Fang, Z. ;

Nguyen, M. ;

Pierce, S. ;

Wei, Y. ;

Parmar, S. ;

Cortes, J. ;

Kantarjian, H. ;

Garcia-Manero, G. .

LEUKEMIA, 2014, 28 (06) :1280-1288

[18] A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes [J].

Zeidan, Amer M. ;

Boss, Isaac ;

Beach, C. L. ;

Copeland, Wilbert B. ;

Thompson, Ethan ;

Fox, Brian A. ;

Hasle, Vanessa E. ;

Ogasawara, Ken ;

Cavenagh, James ;

Silverman, Lewis R. ;

Voso, Maria Teresa ;

Hellmann, Andrzej ;

Tormo, Mar ;

O'Connor, Tim ;

Previtali, Alessandro ;

Rose, Shelonitda ;

Garcia-Manero, Guillermo .

BLOOD ADVANCES, 2022, 6 (07) :2207-2218

← 1 2 →